| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on November 23, 2005
Accepted on February 16, 2006
Department of Endocrinology and Metabolic Diseases, Neurosurgery, and Radiotherapy, Leiden University Medical Center, Leiden, The Netherlands
* To whom correspondence should be addressed. E-mail: o.m.dekkers{at}lumc.nl.
Objective: Transsphenoidal surgery is the treatment of choice for non-functioning pituitary macroadenomas (NFMA). In this study we evaluated the long-term effects of a treatment strategy, in which postoperative radiotherapy was not routinely applied to patients with NFMA.
Design: Retrospective follow-up study
Patients: We included 109 consecutive patients (age 56 ± 13 yr) operated for NFMA between 1992 and 2004.
Results: Radiological imaging revealed a macro-adenoma in all patients, with suprasellar extension in 96% and parasellar/infrasellar extension in 36% of cases. Visual field defects were present in 87% of the patients and improved in 84% of these patients after surgery. Only six patients received postoperative radiotherapy. Ten patients died during the follow-up period. Ninety-seven patients could be assessed for tumor regrowth or tumor recurrence after a mean follow-up period of 6.0 ± 3.7 yr. In 9 patients there was evidence for tumor regrowth, and in one patient tumor recurrence was observed. The mean time to tumor growth/recurrence after initial therapy was 6.9 (range 3-12) years. Follow-up duration was found to be an independent predictor for tumor regrowth.
Conclusion: Transsphenoidal surgery without postoperative radiotherapy is an effective and safe treatment strategy for NFMA, without evidence for tumor regrowth in 90% of all patients, at least for the duration of follow up presented in this study. Additional studies are required to exclude higher regrowth and recurrence rates during prolongation of the duration of follow up.
This article has been cited by other articles:
 |
|
 |
|
  S. Melmed Update in Pituitary Disease J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 331 - 338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. van der Klaauw, O. M. Dekkers, A. M. Pereira, K. W. van Kralingen, and J. A. Romijn Increased Daytime Somnolence despite Normal Sleep Patterns in Patients Treated for Nonfunctioning Pituitary Macroadenoma J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 3898 - 3903. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Dubois, S Guyetant, P Menei, P Rodien, F Illouz, B Vielle, and V Rohmer Relevance of Ki-67 and prognostic factors for recurrence/progression of gonadotropic adenomas after first surgery Eur. J. Endocrinol., August 1, 2007; 157(2): 141 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Buchfelder, P. H. Kann, C. Wuster, U. Tuschy, B. Saller, G. Brabant, A. Kleindienst, P. Nomikos, and the German KIMS Board Influence of GH substitution therapy in deficient adults on the recurrence rate of hormonally inactive pituitary adenomas: a case control study Eur. J. Endocrinol., August 1, 2007; 157(2): 149 - 156. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. M. Dekkers, N. R. Biermasz, A. M. Pereira, F. Roelfsema, M. O. van Aken, J. H. C. Voormolen, and J. A. Romijn Mortality in Patients Treated for Cushing's Disease Is Increased, Compared with Patients Treated for Nonfunctioning Pituitary Macroadenoma J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 976 - 981. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O M Dekkers, S Hammer, R J W de Keizer, F Roelfsema, P J Schutte, J W A Smit, J A Romijn, and A M Pereira The natural course of non-functioning pituitary macroadenomas Eur. J. Endocrinol., February 1, 2007; 156(2): 217 - 224. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. P. Singh and V. K. Panwar Case report of a pituitary macroadenoma treated with artemether. Integr Cancer Ther, December 1, 2006; 5(4): 391 - 394. [Abstract] [PDF]
|
|
|
|
|
|
O. M. Dekkers, A. A. van der Klaauw, A. M. Pereira, N. R. Biermasz, P. J. Honkoop, F. Roelfsema, J. W. A. Smit, and J. A. Romijn Quality of Life Is Decreased after Treatment for Nonfunctioning Pituitary Macroadenoma J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3364 - 3369. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
